CClinicalTrials.gg
Sign In
CompletedNCT02248844Updated Jul 5, 2019

Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea

An observational study in Lateral Canthal Lines and Crow's Feet Lines, sponsored by Allergan. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-05.

Sponsored by Allergan · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
667
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a postmarketing surveillance study in Korea to evaluate the safety and effectiveness of BOTOX® for lateral canthal lines (crow's feet lines) with or without simultaneous glabellar lines.

02

Conditions studied

  • Lateral Canthal Lines
  • Crow's Feet Lines
03

In context

Lead sponsor

Allergan is the lead sponsor of 499 studies on the registry; none are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 89 (98%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with Lateral Canthal Lines (Crow's Feet Lines)

Inclusion criteria

  • Subject and Investigator decision to treat crow's feet lines with Botox®

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
667 participants (actual)
Patient registry
No

Groups and cohorts

  • Botulinum Toxin Type A

    Subjects who receive botulinum toxin Type A injected into crow's feet line areas per clinical practice.

    Biological: Botulinum Toxin Type A

Interventions

  • BiologicalBotulinum Toxin Type A

    Botulinum toxin Type A injected into crow's feet line areas per clinical practice.

    Also known as: BOTOX®, onabotulinumtoxinA

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events

    Time frame: Up to 3 months

Secondary outcomes

  1. Investigator's Assessment of Change in Appearance of Crow's Feet Lines on a 3-Point Scale

    Time frame: Baseline, Up to 3 months

  2. Subject's Assessment of Change in Appearance of Crow's Feet Lines on a 7-Point Scale

    Time frame: Baseline, Up to 3 months

07

Study locations

1 site
  • Dr. Robbin Clinic
    Gangnam-gu, Seoul 135-839, Korea, Republic of
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02248844
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Sep 25, 2014
Start date
Sep 26, 2014
Primary completion
Aug 14, 2017
Completion
Aug 14, 2017
Last update
Jul 5, 2019

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Allergan

Start the discussion